March 23, 2025 - 10:21

Today, the Obesity Action Coalition (OAC) and The Obesity Society (TOS) have taken a significant step by sending a letter to the U.S. Food and Drug Administration (FDA). This letter, supported by over 20 prominent organizations and providers from various sectors of healthcare, emphasizes the urgent need for the FDA to implement and enforce federal regulations concerning compounding practices.
The call to action comes in the wake of recent shortages of GLP-1 medications, which are crucial for the treatment of obesity and related conditions. These shortages have raised serious concerns about patient access to essential therapies. The coalition argues that without stricter oversight and regulation of compounded medications, patients may face continued disruptions in their treatment options.
Healthcare leaders are advocating for a timely response from the FDA to ensure that patients receive the medications they need without interruption, highlighting the importance of regulatory frameworks in safeguarding public health.
May 28, 2026 - 03:00
Colorectal cancer risk linked to gut microbiome alterations | Harvard T.H. Chan School of Public HealthEven more than ten years after a precancerous growth called an adenoma is removed from the colon, the gut microbiome and its related metabolites may still show lasting changes that increase the...
May 27, 2026 - 14:17
A Great Athlete is a Healthy Athlete: Muaz’s Journey to Becoming a Fitness CaptainEvery May, Special Olympics marks Fitness and Sport Month, a time to highlight how physical activity boosts health, performance, and overall well-being for athletes. This year, I sat down with Muaz...
May 26, 2026 - 20:41
Popular fruit may help protect your skin from the sun, new study suggestsA new study suggests that eating grapes might offer a natural layer of protection against the sun`s harmful rays. Published in the journal ACS Nutrition Science, the research indicates that...
May 26, 2026 - 16:16
Optima Health Leads These 3 Undiscovered Gems in the United KingdomAs the FTSE 100 and FTSE 250 struggle under pressure from weak global signals and disappointing trade numbers out of China, many investors are shifting their attention away from big-name blue chips...